Form 4 for PCVX Vaxcyte, Inc.
Accepted 2024-11-04 00:00:00 ET · period of report 2024-11-01 · accession 0001649094-24-000091 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-11-04 | 2024-11-01 | PCVX | PICKERING GRANT | CEO, Dir | S - Sale | $106.82 | -15.0K | 435.2K | -3% | -$1.60M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-01 | S | D | 9,955 | $106.35 | 440,264 | D | — | — | (F2) The price reported is a weighted-average price. The shares were sold at prices ranging from $105.855 to $106.80. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2024-11-01 | S | D | 3,312 | $107.34 | 436,952 | D | — | — | (F3) The price reported is a weighted-average price. The shares were sold at prices ranging from $106.865 to $107.845. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2024-11-01 | S | D | 1,733 | $108.50 | 435,219 | D | — | — | (F4) The price reported is a weighted-average price. The shares were sold at prices ranging from $107.97 to $108.93. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |